cardiovascular markers. Drugs,medicaments and biological substances causing adverse effects in therapeutic use
Conditions
Interventions
Intervention 1: Tibolone 2.5mg/daily for 6 months orally. Intervention 2: Sulfate estrogen conjugate, 0.625 mg + 2.5 mg medroxy progestrone acetate/daily for six months orally. Intervention 3: Calciu
Treatment - Drugs
Tibolone 2.5mg/daily for 6 months orally
Sulfate estrogen conjugate, 0.625 mg + 2.5 mg medroxy progestrone acetate/daily for six months orally
Calcium 500 mg, Vitamine D (200 IU)/daily for six months orally
Sponsors
Tarbiat Modares University
Eligibility
Sex/Gender
Female
Age
45 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: healthy non-surgical postmenopausal women (more than one year since the last menstrual period and plasma 17-ß-estradiol level 250 mg/dl and/or triglyceride (TG) > 150 mg/dl), smoking, presence of diabetes, previous angina, or hypertension
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum lipid. Timepoint: Baseline and after six months. Method of measurement: enzymatic method. | — |
Secondary
| Measure | Time frame |
|---|---|
| CRP. Timepoint: Baseline and after six months. Method of measurement: immuno turb.;BMI. Timepoint: at first and after six months. Method of measurement: meter weight.;SHBG. Timepoint: Baseline and after six months. Method of measurement: ELISA.;FTI. Timepoint: Baseline and after six months. Method of measurement: ELISA.;FEI. Timepoint: Baseline and after six months. Method of measurement: ELISA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Saeideh Ziaei
Tarbiat Modares University
Outcome results
None listed